| |
News
|  January 19, 2010 | | MICHAEL J. FOX FOUNDATION AWARDS RESEARCH GRANT TO ENVIVO AS PART OF INITIATIVE SEEKING NEW PARKINSON’S DISEASE TREATMENTS. |
|
| | January 05, 2010 | | ENVIVO ENTERS PHASE 2B TRIALS FOR ITS EVP-6124 COMPOUND IN THE TREATMENT OF SCHIZOPHRENIA. |
|
| | December 08, 2009 | | EnVivo Pharmaceuticals Announces Results Showing In-Vivo Reduction of Aggregated B-Amyloid. |
|
| | September 29, 2009 | | EnVivo Pharmaceuticals names Stephen DiPalma Chief Financial Officer. |
|
| | July 15, 2009 | | EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer’s Disease. |
|
| | July 14, 2009 | | EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer’s Disease Transgenic Mouse Model With Gamma-Secretase Modulator. |
|
| | April 01, 2009 | | ENVIVO AND MITSUBISHI-TANABE ENTER LICENSE AGREEMENT ON EVP-6124 IN JAPAN, KOREA, TAIWAN AND OTHER ASIAN COUNTRIES. |
|
| | January 12, 2009 | | ENVIVO REPORTS POSITIVE RESULTS OF ITS EVP-6124 CLINICAL BIO-MARKER STUDY IN SCHIZOPHRENIA PATIENTS. |
|
| | September 24, 2008 | | EnVivo Pharmaceuticals Publishes Preclinical Data On EVP-0334. |
|
| | April 02, 2008 | | Envivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in patients with Schizophrenia. |
|
| | February 06, 2008 | | METHYLGENE EXERCISES RIGHT TO OPT-OUT OF HDAC NEURODEGENERATIVE. |
|
| | October 17, 2007 | | EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer’s, Schizophrenia and Huntington’s Diseases. |
|
| | September 25, 2007 | | EnVivo Announces Hiring of Chief Medical Officer. |
|
| | November 16, 2006 | | MethylGene and EnVivo Pharmaceuticals Form Collaboration with CHDI, Inc., in Support of HDAC Program for Huntington’s Disease. |
|
| | October 25, 2006 | | EnVivo Pharmaceuticals Forms Research Collaboration With CHDI. |
|
| | October 04, 2006 | | EnVivo Secures $24 Million in Series C Financing. |
|
| | May 23, 2006 | | EnVivo Expands Management Team as Company Prepares First Drugs for Clinical Trials. |
|
| | June 27, 2005 | | EnVivo Appoints Kees Been as Chief Executive Officer. |
|
| | February 01, 2005 | | Methylgene and EnVivo sign HDAC Collaboration Agreement. |
|
| | November 09, 2004 | | EnVivo Pharmaceuticals Secures $23 Million Series B Funding. |
|
| | August 17, 2004 | | EnVivo Announces Hiring of Vice President of Chemistry. |
|
| | July 19, 2004 | | MethylGene and EnVivo Pharmaceuticals to collaborate in Neurodegenerative Diseases. |
|
| | December 05, 2003 | | EnVivo Appoints Several Leaders to Its Scientific Advisory Board. |
|
| | November 17, 2003 | | EnVivo Announces Key Additions to Its Management Team. |
|
| | October 27, 2003 | | EnVivo Pharmaceuticals Has Moved to Watertown, Massachusetts. |
|
| | October 06, 2002 | | EnVivo Pharmaceuticals Closes $14.7M Series A Round Led by Fidelity BioSciences Group. |
|
| | October 01, 2002 | | EnVivo Pharmaceuticals Awarded NIH Grant to Develop Technology for CNS Drug Discovery. |
|
Events
Huntington’s Disease Summit – July 29, 2005
- EnVivo hosted a summit on development of therapies for Huntington’s Disease that was attended by leading researchers and clinicians for Huntington’s Disease.
Therapeutic Strategies against Neurodegenerative Conditions (TSANC) – October 10-11, 2005, Boston, MA
- Dr. Gerhard Koenig, CSO will give a presentation titled “Building a Pipeline of Novel Therapeutics for Neurodegenerative Diseases Using Phenotypic Screening”.
- http://gtcbio.com/confpage.asp?cid=19
Mass Opportunities: A Biotechnology Investment Conference – November 3, 2005, Boston, MA
BIO-Europe 2005 – November 7-9, 2005, Dresden, Germany
|
